Showing results (71-80 of 776) with videos related to
Sort By:
Pageof 78
The Journal of Biological Chemistry|March 2, 2002
NF-kappa B as a therapeutic target in multiple myelomaTeru Hideshima, Dharminder Chauhan, Paul Richardson, et al.Current Medicinal Chemistry. Anti-Cancer Agents|April 8, 2003
Telomerase inhibitors as anticancer therapyMasaharu Akiyama, Teru Hideshima, Nikhil C Munshi, et al.Oncology (Williston Park, N.Y.)|March 2, 2006
New treatments for multiple myelomaPaul G Richardson, Robert Schlossman, Teru Hideshima, et al.Therapeutics and Clinical Risk Management|August 30, 2008
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myelomaTeru Hideshima, Noopur Raje, Paul G Richardson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
The emerging role of novel therapies for the treatment of relapsed myelomaPaul G Richardson, Teru Hideshima, Constantine Mitsiades, et al.Expert Review of Anticancer Therapy|August 24, 2006
Lenalidomide in multiple myelomaPaul G Richardson, Constantine Mitsiades, Teru Hideshima, et al.Blood|June 26, 2004
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosisSteven Le Gouill, Klaus Podar, Martine Amiot, et al.Blood|May 14, 2009
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cellsTeru Hideshima, Hiroshi Ikeda, Dharminder Chauhan, et al.Blood|March 16, 2010
A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cellsTeru Hideshima, Constantine Mitsiades, Hiroshi Ikeda, et al.Blood|October 7, 2006
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Klaus Podar, Marc S Raab, Jing Zhang, et al.Pageof 78